ClinicalTrials.gg
CompletedNCT04821063Updated Jan 11, 2024Results posted

Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval

A Phase 1 interventional study of ITF2357 10 mg/mL and ITF2357 10 mg/mL in Duchenne and Becker Muscular Dystrophy and Polycytemia Vera, sponsored by Italfarmaco. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-11.

Sponsored by Italfarmaco · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 65 studies in Muscular Dystrophy, Duchenne with a site in Canada — 5 open to participants now, 14 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · Canada.

Enrollment
46th of 61
31 · median 70
Started
2021
with 3 others
Phase 1
4 of 65
none open now
Registered
53rd of 65
by date
Lead sponsor
4 of 65
Italfarmaco

Among the 65 studies in Muscular Dystrophy, Duchenne with a site in Canada, this one is the 46th largest by enrollment of the 61 interventional ones that give a count, is one of 4 that started in 2021, is one of 4 in phase 1, and was the 53rd registered.

Muscular Dystrophy, Duchenne

481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

5 of the 65 studies in Muscular Dystrophy, Duchenne with a site in Canada are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Muscular Dystrophy, Duchenne with a site in Canada, or all of them as a file.
02

Study summary

The study will evaluate the effect of a therapeutic dose and a supratherapeutic dose of ITF2357 on the QT/QTc interval.

03

Conditions studied

  • Duchenne and Becker Muscular Dystrophy
  • Polycytemia Vera
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, non-smoker (no use of tobacco or nicotine products within 3 months prior to screening), greater than or equal to (>=) 18 and less than or equal to (\<=) 55 years of age, with (BMI) greater than (>) 18.5 and less than (\<) 30.0 kilograms per meter square (kg/m\^2) and body weight >=55 kilograms (kg) and \<=100 kg for females and body weight >=60 kg and \<=100 kg for males.
  2. Healthy as defined by:

    1. The absence of illness and major surgery within 4 weeks prior to dosing. Participants vomiting within 24 hours pre-dose will be carefully evaluated for upcoming illness/disease. Inclusion pre-dosing of the patient in the study is at the discretion of the Investigator, depending on his/her clinical judgement.
    2. The absence of clinically significant history of neurological, endocrinal, cardiovascular, pulmonary, hematological, immunologic, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.
  3. Non- female defined as:

    1. female (absence of menses for 12 months prior to the first study drug administration, bilateral oophorectomy or hysterectomy with bilateral oophorectomy at least 6 months prior to the first study drug administration); or
    2. Surgically sterile female (hysterectomy or tubal ligation at least 6 months prior to drug administration).
  4. Females of childbearing potential who are sexually active with a male partner must be willing to use one of the following acceptable methods throughout the study and for at least 90 days after the last study drug administration:

    1. Simultaneous use of intra-uterine contraceptive device, without hormone release system placed at least 4 weeks prior to study drug administration, and condom for the male partner;
    2. Simultaneous use of diaphragm or cervical cap with intravaginally applied spermicide and male condom for the male partner, started at least 21 days prior to study drug administration;
  5. Male participants who are not vasectomized for at least 6 months, and who are sexually active with a female partner of childbearing potential (childbearing potential females are defined as women that are neither post-menopausal nor surgically sterile) must be willing to use one of the following acceptable contraceptive methods from the first study drug administration until at least 90 days after the last study drug administration:

    1. Simultaneous use of a male condom and, for the female partner, hormonal contraceptives used since at least 4 weeks or intra-uterine contraceptive device placed since at least 4 weeks;
    2. Simultaneous use of a male condom and, for the female partner, a diaphragm or cervical cap with intravaginally applied spermicide.
  6. Male participants (including men who have had a vasectomy) with a pregnant partner must agree to use a condom from the first study drug administration until at least 90 days after the last study drug administration.
  7. Male participants must be willing not to donate sperm until 90 days following the last study drug administration.
  8. Female participants must be willing not to donate ovules until 90 days following the last study drug administration.
  9. Participant's written obtained prior to any study-related procedure.
  10. Willingness and capability to comply with the requirements of the study and ability to understand the study procedures and the risks involved.
  11. Willing to take out dentures and mouth piercings for study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Any abnormality at physical examination, clinically significant abnormal laboratory test results or positive test for (HIV), , or found during medical screening.
  2. Clinically significant vital sign abnormalities (systolic blood pressure lower than 90 or over 140 millimeter of mercury [mmHg], diastolic blood pressure lower than 60 or over 90 mmHg, or heart rate less than 40 or over 100 beats per minute [bpm]) at screening. For eligibility purposes, not the mean value, but the two single measurements will be considered.
  3. Any of the following abnormalities on 12-lead at screening. PR (PR interval) >210 millisecond (msec); QRS (QRS complex) >120 msec; >450 msec; any abnormality of cardiac rhythm other than sinus arrhythmia; abnormality of T-wave morphology that will impair the ability to measure the QT interval reliably. The averaged value of three ECGs 5 minutes apart from each other will be used; evaluations have to be used for the evaluation of the QTc interval requested by this exclusion criteria.
  4. Participants with history of sustained and non-sustained cardiac arrhythmias (ECG demonstrated), participants with a family history of sudden cardiac death and participants with a history of additional risk factors for TdP, heart failure, hypokalemia, LQTS).
  5. Any of the following abnormal laboratory test values at screening or at baseline (Day -1) of Period 1:

    1. count \<125*10\^9 per liter (/L)
    2. \<1.2*10\^9/L
  6. Participants who have cardiovascular condition such as, but not limited to unstable ischemic heart disease, (NYHA) Class III/IV left ventricular failure, acute ischemic heart disease in the last year prior to study screening, which may impact the safety of the participant or the evaluation of the result of the study according to the Investigator's judgment; cardiovascular conditions should be discarded based on the results obtained on the ECG, medical examination and routine lab test.
  7. Positive urine drug screen, alcohol breath test or urine cotinine test at screening or at baseline (Day -1).
  8. History of anaphylaxis reaction or clinically significant drug reaction (e.g., angioedema, Stevens-Johnson syndrome, Acute Generalized Exanthematous Pustulosis, Drug-induced hypersensitivity syndrome, Drug-induced neutropenia).
  9. History of allergic reactions to ITF2357, histone deacetylases (HDAC) inhibitors, or other related drugs, moxifloxacin, other quinolones, or to any in the formulation.
  10. Positive pregnancy test at screening or at baseline (Day -1).
  11. Participants with a sorbitol intolerance or sorbitol malabsorption or have fructose intolerance.
  12. Current or recent (within 3 months of study drug administration) clinically significant gastrointestinal disease that can interfere with drug absorption.
  13. Gastrointestinal surgery that interferes with physiological absorption and motility (i.e., gastric bypass, duodenectomy) or gastric bands.
  14. History of significant alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to the screening visit (more than 14 units of alcohol per week [1 unit = 150 milliliter [mL] of wine, 360 mL of beer, or 45 mL of 40 percent [%] alcohol]).
  15. History of significant drug abuse within 1 year prior to screening or use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and amphetamine derivatives) within 1 year prior to screening.
  16. Use of ITF2357 for a medical condition or in the context of another clinical trial within a period of 30 days prior to the first dosing.
  17. Participation in a clinical research study involving the administration of an or marketed drug or device within 30 days prior to the first dosing, administration of a biological product in the context of a clinical research study within 90 days prior to the first dosing, or concomitant participation in an investigational study involving no drug or device administration.
  18. Use of medications for the timeframes specified below, with the exception of medications exempted by the Investigator on a case-by-case basis because they are judged unlikely to affect the pharmacokinetic profile of the study drug or participant safety (e.g., topical drug products without significant systemic absorption):

    1. Prescription medications within 14 days prior to the first dosing;
    2. OTC products (with the exception of the occasional use of acetaminophen [up to 2 grams [g] daily]) and natural health products (including herbal remedies, homeopathic and traditional medicines, probiotics, food supplements such as vitamins, minerals, amino acids, essential fatty acids, and protein supplements used in sports) within 7 days prior to the first dosing;
    3. Depot injection or implant of any drug within 3 months prior to the first dosing;
    4. Any drugs known to induce or inhibit hepatic drug metabolism (including St. John's wort) within 30 days prior to the first dosing.
  19. Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at screening) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the first dosing.
  20. Breast-feeding participant.
  21. Inability to be venipunctured and/or tolerate catheter venous access;
  22. Inability or difficulty to swallow tablets or suspension.
  23. Any reason which, in the opinion of the Investigator, would prevent the participant from participating in the study.
  24. History or presence of other diseases, metabolic dysfunctions, physical examination findings, or any clinically relevant abnormal laboratory value at screening suggesting an unknown disease and requiring further clinical investigation or which may impact the safety of the participant or the evaluation of the result of the study according to the Investigator's judgment.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Therapeutic dose: ITF2357 100 mg

    Participants will receive a single dose of ITF2357 100 mg administered as 10 milliliters (mL) of ITF2357 10 milligrams per milliliter (mg/mL) oral suspension and 20 mL of placebo matched to ITF2357 oral suspension under fasting conditions on Day 1 of respective period as per the assigned treatment sequence.

    Drug: ITF2357 10 mg/mL · Drug: Placebo

  • Experimental
    Supratherapeutic dose: ITF2357 300 mg

    Participants will receive a single dose of ITF2357 300 mg administered as 30 mL of ITF2357 10 mg/mL oral suspension under fasting conditions on Day 1 of respective period as per the assigned treatment sequence.

    Drug: ITF2357 10 mg/mL

  • Placebo comparator
    Placebo

    Participants will receive a single dose of placebo matched to ITF2357 administered as 30 mL oral suspension under fasting conditions on Day 1 of respective period as per the assigned treatment sequence.

    Drug: Placebo

  • Active comparator
    Moxifloxacin

    Participants will receive a single dose of moxifloxacin 400 mg tablet under fasting conditions on Day 1 of respective period as per the assigned treatment sequence.

    Drug: Moxifloxacin Hydrochloride

Interventions

  • DrugITF2357 10 mg/mL

    Drug page: Givinostat

    Dose: 100 mg (administered as 10 mL); Dosage form: suspension; Route of administration: oral

    Also known as: Givinostat

  • DrugITF2357 10 mg/mL

    Drug page: Givinostat

    Dose: 300 mg (administered as 30 mL); Dosage form: suspension; Route of administration: oral

    Also known as: Givinostat

  • DrugPlacebo

    Dose: 20 mL; Dosage form: suspension; Route of administration: oral

  • Dose: 400 mg; Dosage form: tablet; Route of administration: oral

  • DrugPlacebo

    Dose: 30 mL; Dosage form: suspension; Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Placebo-corrected Change From Baseline in Fridericia's Corrected QT Interval (QTcF)

    The cardio-dynamic assessment was performed through 12-lead electrocardiogram (ECG) extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcF. Placebo-corrected change from baseline in QTcF (ΔΔQTcF) was calculated based on model-predicted effect.

    Time frame: At 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, and 36 hours post-dose

Secondary outcomes

  1. Change From Baseline in QTcF Interval

    The cardio-dynamic assessment was performed through 12-lead ECGs extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. QT interval was corrected for heart rate using Fridericia's correction (QTcF).

    Time frame: At 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, and 36 hours post-dose

  2. Change From Baseline in PR Interval

    The cardio-dynamic assessment was performed through 12-lead ECGs extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The PR interval is the time from the onset of the P-wave to the start of the next QRS complex, corresponding to the end of atrial depolarization and onset of ventricular depolarization.

    Time frame: At 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, and 36 hours post-dose

  3. Change From Baseline in QRS Interval

    The cardio-dynamic assessment was performed through 12-lead ECGs extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. QRS interval is the time from electrocardiogram Q wave to the end of the S wave, corresponding to ventricle depolarization.

    Time frame: At 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, and 36 hours post-dose

  4. Change From Baseline in Heart Rate (HR) Interval

    The cardio-dynamic assessment was performed through 12-lead ECGs extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. Baseline is defined as the last results (scheduled or unscheduled) obtained prior to drug administration in each period.

    Time frame: At 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, and 36 hours post-dose

  5. Placebo-corrected Change From Baseline in PR Interval

    Placebo-corrected change from Baseline in PR, (ΔΔPR) was calculated based on model-predicted effect. PR interval was the time between the beginning of the P wave and the start of the QRS interval, corresponding to the end of atrial depolarization and onset of ventricular depolarization.

    Time frame: At 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, and 36 hours post-dose

  6. Placebo-corrected Change From Baseline in QRS Interval

    Placebo-corrected change from baseline for QRS interval, (ΔΔQRS) was calculated based on model-predicted effect. QRS interval is the time from Q wave to the end of the S wave, corresponding to ventricle depolarization.

    Time frame: At 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, and 36 hours post-dose

  7. Placebo-corrected Change From Baseline in HR Interval

    Placebo-corrected change from baseline in HR, (ΔΔHR) was calculated based on model-predicted effect.

    Time frame: At 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, and 36 hours post-dose

  8. Number of Participants With Changes in Categorical Outliers for QTcF, PR, and QRS Intervals in the ECG and HR

    QTcF: Treatment-emergent value of greater than (\>) 450 and less than or equal to (\<=) 480 ms when not present at Baseline (new onset). Treatment-emergent value of \> 480 and \<= 500 ms when not present at Baseline (new onset). Treatment-emergent value of \> 500 ms when not present at Baseline (new onset). Increase of QTcF (ΔQTcF) from Baseline of \> 30 and \<= 60 ms. Increase of QTcF from Baseline \> 60 ms HR: Decrease of HR from Baseline \> 25% resulting in HR less than (\<) 50 bpm. Increase of HR from Baseline \> 25% resulting in HR \> 100 bpm. PR: Increase of PR from Baseline \> 25% resulting in PR \> 210 ms. QRS: Increase of QRS from Baseline \> 25% resulting in QRS \> 120 ms.

    Time frame: Baseline, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, and 36 hours post-dose

  9. Number of Participants With Treatment-Emergent Changes of T-Wave Morphology and U Wave Presence

    T-wave abnormalities were categorized as follows: Normal T wave (+): Any positive T wave not meeting any criterion below. Flat T wave: T amplitude \< 1 mm (either positive or negative) including flat isoelectric line. Notched T wave (+): Presence of notch(es) of at least 0.05 mV amplitude on ascending or descending arm of the positive T wave. Biphasic: T wave that contains a second component with an opposite phase that is at least 0.1 mV deep (both positive/negative and negative/positive and polyphasic T waves included). Normal T wave (-): T amplitude that is negative, without biphasic T wave or notches. Notched T wave (-): Presence of notch(es) of at least 0.05 mV amplitude on descending or ascending arm of the negative T wave. U waves: Presence of abnormal U waves.

    Time frame: Up to 44 days

  10. Plasma Pharmacokinetic (PK): Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of ITF2357 and Its Metabolites

    The area under the concentration time curve (AUC) from time zero (= dosing time) to the last sampling time (tlast) at which the concentration is at or above the lower limit of quantification. AUC0-t was calculated using the mixed log-linear trapezoidal rule (linear up, log down). AUC0-t of ITF2357 and metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide were reported.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose

  11. Plasma PK: Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Moxifloxacin

    The area under the concentration time curve (AUC) from time zero (= dosing time) to the last sampling time (tlast) at which the concentration is at or above the lower limit of quantification. AUC0-t was calculated using the mixed log-linear trapezoidal rule (linear up, log down).

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose

  12. Plasma PK: Area Under the Concentration-Time Curve From Time Zero to 12 Hours (AUC0-12) of ITF2357 and Its Metabolites

    AUC0-12 was calculated using the trapezoidal method for ITF2357 and metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide. AUC0-12:: of ITF2357 and its metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide were reported.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 12 hours post-dose

  13. Plasma PK: Area Under the Concentration-Time Curve From Time Zero to 12 Hours (AUC0-12) of Moxifloxacin

    AUC0-12 was calculated using the trapezoidal method for Moxifloxacin.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8 and 12 hours post-dose

  14. Plasma PK: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of ITF2357 and Its Metabolites

    AUC0-inf was calculated as AUC0-t + Clast/Kel, where Clast is the last measurable concentration. Elimination rate constant (Kel),was defined as the negative of the estimated slope of the linear regression of the in-transformed concentration versus time profile in the terminal elimination phase. AUC0-inf of ITF2357 and metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide were reported.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose

  15. Plasma PK: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Moxifloxacin

    AUC0-inf was calculated as AUC0-t + Clast/Kel, where Clast is the last measurable concentration for Moxifloxacin.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose

  16. Plasma PK: Percentage of Residual Area for ITF2357 and Its Metabolites

    Residual area was calculated as 100\*(1- AUC0-t / AUC0-inf) for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose

  17. Plasma PK: Percentage of Residual Area for Moxifloxacin

    Residual area was calculated as 100\*(1- AUC0-t / AUC0-inf) for moxifloxacin.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose

  18. Plasma PK: Maximum Observed Plasma Concentration (Cmax) of ITF2357 and Its Metabolites

    Cmax was calculated for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide. Cmax was taken directly from the observed concentration-time curve.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose

  19. Plasma PK: Maximum Observed Plasma Concentration (Cmax) of Moxifloxacin

    Cmax was calculated for moxifloxacin. Cmax was taken directly from the observed concentration-time curve.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose

  20. Plasma PK: Time of Observed Cmax (Tmax) of ITF2357 and Its Metabolites

    Tmax was calculated for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide. The time to reach the maximum observed plasma concentration obtained directly from plasma concentration time curve.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose

  21. Plasma PK: Time of Observed Cmax (Tmax) of Moxifloxacin

    Tmax was calculated for Moxifloxacin. The time to reach the maximum observed plasma concentration obtained directly from plasma concentration time curve.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose

  22. Plasma PK: Elimination Rate Constant (Kel) of ITF2357 and Its Metabolites

    Kel was defined as the negative of the estimated slope of the linear regression of the ln-transformed concentration versus time profile in the terminal elimination phase. Kel was calculated for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, andITF2955 glucuronide.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose

  23. Plasma PK: Elimination Rate Constant (Kel) of Moxifloxacin

    Kel was defined as the negative of the estimated slope of the linear regression of the ln-transformed concentration versus time profile in the terminal elimination phase. Kel was calculated for Moxifloxacin.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose

  24. Plasma PK: Elimination Half-life (T½ el) of ITF2357 and Its Metabolites

    T½ el was calculated as ln(2)/kel for ITF2357 and Metabolites : ITF2374, ITF2375, ITF2440, ITF2563, ITF2955 glucuronide, and Moxifloxacin.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose

  25. Plasma PK: Elimination Half-life (T½ el) of Moxifloxacin

    T½ el was calculated as ln(2)/kel for moxifloxacin.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose

  26. Plasma PK: Apparent Total Body Clearance (CL/F) of ITF2357 and Its Metabolites

    CL/F was calculated as Dose/AUC0-inf for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose

  27. Plasma PK: Apparent Total Body Clearance (CL/F) of Moxifloxacin

    CL/F was calculated as Dose/AUC0-inf for moxifloxacin.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose

  28. Plasma PK: Apparent Volume of Distribution (Vd/F) of ITF2357 and Its Metabolites

    Vd/F was calculated as Dose/Kel x AUC0-inf for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose

  29. Plasma PK: Apparent Volume of Distribution (Vd/F) of Moxifloxacin

    Vd/F was calculated as Dose/Kel x AUC0-inf for moxifloxacin.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose

  30. Urine PK: Cumulative Urinary Excretion From Time Zero to Time t (Ae0-t) for ITF2357 and Its Metabolites

    Ae0-t was calculated as the sum of the amounts excreted over each collection interval. The amount excreted in the urine for each time interval is calculated as the urine concentration multiplied by the urine volume for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, ITF2955 glucuronide.

    Time frame: Pre-dose (within 2 hours before dosing), 0-8 hours, 8-24 hours, 24-48 hours, and 48-72 hours post-dose

  31. Urine PK: Maximum Rate of Urinary Excretion (Rmax) for ITF2357 and Its Metabolites

    Rmax was calculated by dividing the amount of drug excreted in each collection interval by the time over which it was collected for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, ITF2955 glucuronide.

    Time frame: Pre-dose (within 2 hours before dosing), 0-8 hours, 8-24 hours, 24-48 hours, and 48-72 hours post-dose

  32. Urine PK: Time of Rmax (TRmax) for ITF2357 and Its Metabolites

    TRmax was calculated as the midpoint of the collection interval during which Rmax occurred for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, ITF2955 glucuronide.

    Time frame: Pre-dose (within 2 hours before dosing), 0-8 hours, 8-24 hours, 24-48 hours, and 48-72 hours post-dose

  33. Urine PK: Renal Clearance (Clr) for ITF2357 and Its Metabolites

    Clr was calculated as Ae0-t / AUC0-t (plasma) for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, ITF2955 glucuronide.

    Time frame: Pre-dose (within 2 hours before dosing), 0-8 hours, 8-24 hours, 24-48 hours, and 48-72 hours post-dose

  34. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

    Adverse event (AE) was defined as any untoward medical occurrence in a subject or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with the study drug. Serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; required initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE were defined as an AEs following the start of treatment or AEs increasing in severity during treatment. TEAEs include both serious and non-serious TEAEs.

    Time frame: Baseline up to 44 days

  35. Number of Treatment-Related TEAEs

    Adverse event (AE) was defined as any untoward medical occurrence in a subject or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with the study drug. Any AEs which occurred due to study drug treatment are reported as Treatment-related AEs. Number of treatment related TEAEs were reported.

    Time frame: Baseline up to 44 days

  36. Number of TEAEs Based on Severity

    All AEs were analyzed using National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0 and were graded as Grade 1: mild asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated, Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL), Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL, Grade 4: Life-threatening consequences; urgent intervention indicated, Grade 5: death related AE, where higher grade indicated more severe condition. Number of TEAEs based on severity were reported.

    Time frame: Baseline up to 44 days

  37. Number of Participants With Clinically Significant Changes in Vital Signs

    Vital signs, including semi supine blood pressure, pulse rate, respiratory rate, weight, and oral temperature were assessed. Clinical significance was decided by the investigator. Number of participants with clinically significant change from baseline in vital signs were reported.

    Time frame: Baseline up to 44 days

  38. Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters

    Clinical laboratory parameters included biochemistry, hematology, and urinalysis. Clinical significance was decided by the investigator. Number of participants with clinically significant change from baseline in clinical laboratory parameters were reported.

    Time frame: Baseline up to 44 days

  39. Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Findings

    ECG parameters included rhythm, ventricular rate, PR interval, QRS duration, and QT interval. Clinical significance was decided by the investigator. Number of participants with clinically significant change from baseline in ECG were reported.

    Time frame: Baseline up to 44 days

07

Results

Posted Jan 11, 2024

Participant flow

The study was conducted at a single center in Canada. A total of 34 healthy non-smoker were screened in the study, of which 31 participants were enrolled and received the study treatment. Screen failures were mainly due to not meeting inclusion criteria.

Period 1 (1 Day)
Participant flow — Period 1 (1 Day)
MilestoneSequence TSTPMSequence STMTPSequence PTMSTSequence MPSTTSequence STPTMSequence PMSTTSequence TSTMPSequence MTPSTSequence PTSTMSequence TMPSTSequence STPMTSequence MSTTP
Started112333333333
Completed112333333333
Not completed000000000000
Washout Period (7 Days )
Participant flow — Washout Period (7 Days )
MilestoneSequence TSTPMSequence STMTPSequence PTMSTSequence MPSTTSequence STPTMSequence PMSTTSequence TSTMPSequence MTPSTSequence PTSTMSequence TMPSTSequence STPMTSequence MSTTP
Started112333333333
Completed112333333333
Not completed000000000000
Period 2 (1 Day)
Participant flow — Period 2 (1 Day)
MilestoneSequence TSTPMSequence STMTPSequence PTMSTSequence MPSTTSequence STPTMSequence PMSTTSequence TSTMPSequence MTPSTSequence PTSTMSequence TMPSTSequence STPMTSequence MSTTP
Started112333333333
Completed112333333333
Not completed000000000000
Washout Period (7 Days)
Participant flow — Washout Period (7 Days)
MilestoneSequence TSTPMSequence STMTPSequence PTMSTSequence MPSTTSequence STPTMSequence PMSTTSequence TSTMPSequence MTPSTSequence PTSTMSequence TMPSTSequence STPMTSequence MSTTP
Started112333333333
Completed112333333333
Not completed000000000000
Period 3 (1 Day)
Participant flow — Period 3 (1 Day)
MilestoneSequence TSTPMSequence STMTPSequence PTMSTSequence MPSTTSequence STPTMSequence PMSTTSequence TSTMPSequence MTPSTSequence PTSTMSequence TMPSTSequence STPMTSequence MSTTP
Started112333333333
Completed112333333333
Not completed000000000000
Washout Period 3 (7 Days)
Participant flow — Washout Period 3 (7 Days)
MilestoneSequence TSTPMSequence STMTPSequence PTMSTSequence MPSTTSequence STPTMSequence PMSTTSequence TSTMPSequence MTPSTSequence PTSTMSequence TMPSTSequence STPMTSequence MSTTP
Started112333333333
Completed112333333333
Not completed000000000000
Period 4 (1 Day)
Participant flow — Period 4 (1 Day)
MilestoneSequence TSTPMSequence STMTPSequence PTMSTSequence MPSTTSequence STPTMSequence PMSTTSequence TSTMPSequence MTPSTSequence PTSTMSequence TMPSTSequence STPMTSequence MSTTP
Started112333333333
Completed112333333333
Not completed000000000000

Outcome measures

PrimaryPlacebo-corrected Change From Baseline in Fridericia's Corrected QT Interval (QTcF)

The cardio-dynamic assessment was performed through 12-lead electrocardiogram (ECG) extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcF. Placebo-corrected change from baseline in QTcF (ΔΔQTcF) was calculated based on model-predicted effect.

Time frame:
At 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, and 36 hours post-dose
Reported as:
Least squares mean · Milliseconds (msec)
Placebo-corrected Change From Baseline in Fridericia's Corrected QT Interval (QTcF)
Milliseconds (msec)Therapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mgMoxifloxacin
0.5 hours post-dose1.0 ± 1.060.5 ± 1.0410.2 ± 1.05
1 hours post-dose0.3 ± 1.010.8 ± 0.9913.1 ± 1.00
1.5 hours Post-dose1.0 ± 0.992.7 ± 0.9712.3 ± 0.98
2 hours Post-dose2.1 ± 1.004.3 ± 0.9814.0 ± 0.99
2.5 hours Post-dose3.6 ± 1.176.1 ± 1.1514.8 ± 1.16
3 hours Post-dose2.3 ± 1.066.6 ± 1.0414.0 ± 1.05
3.5 hours Post-dose2.8 ± 1.149.1 ± 1.1212.8 ± 1.13
4 hours Post-dose4.0 ± 1.1310.4 ± 1.1111.9 ± 1.12
5 hours Post-dose5.5 ± 2.1113.6 ± 2.0812.1 ± 2.09
6 hours Post-dose3.8 ± 1.8211.4 ± 1.799.7 ± 1.81
7 hours Post-dose3.0 ± 1.769.2 ± 1.739.6 ± 1.74
8 hours Post-dose3.5 ± 1.5711.5 ± 1.5411.3 ± 1.55
12 hours Post-dose2.5 ± 1.8510.2 ± 1.827.9 ± 1.83
24 hours Post-dose2.3 ± 1.6211.0 ± 1.595.6 ± 1.61
36 hours Post-dose-0.9 ± 1.861.5 ± 1.831.8 ± 1.84
SecondaryChange From Baseline in QTcF Interval

The cardio-dynamic assessment was performed through 12-lead ECGs extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. QT interval was corrected for heart rate using Fridericia's correction (QTcF).

Time frame:
At 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, and 36 hours post-dose
Reported as:
Least squares mean · msec
Change From Baseline in QTcF Interval
msecTherapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mgMoxifloxacinPlacebo
0.5 hours Post-dose-0.7 ± 0.88-1.3 ± 0.868.5 ± 0.87-1.8 ± 0.86
1 hours Post-dose-0.3 ± 0.850.2 ± 0.8312.5 ± 0.84-0.6 ± 0.83
1.5 hours Post-dose0.8 ± 0.842.5 ± 0.8112.1 ± 0.82-0.2 ± 0.81
2 hours Post-dose1.3 ± 0.853.6 ± 0.8213.2 ± 0.83-0.8 ± 0.82
2.5 hours Post-dose3.1 ± 0.955.5 ± 0.9314.2 ± 0.94-0.5 ± 0.93
3 hours Post-dose2.9 ± 0.887.1 ± 0.8614.5 ± 0.870.5 ± 0.86
3.5 hours Post-dose4.5 ± 0.9310.7 ± 0.9114.4 ± 0.921.6 ± 0.91
4 hours Post-dose6.0 ± 0.9312.4 ± 0.9013.9 ± 0.912.0 ± 0.90
5 hours Post-dose4.0 ± 1.5812.1 ± 1.5310.6 ± 1.56-1.5 ± 1.53
6 hours Post-dose0.4 ± 1.388.1 ± 1.346.3 ± 1.36-3.3 ± 1.34
7 hours Post-dose-2.3 ± 1.343.8 ± 1.304.3 ± 1.32-5.3 ± 1.30
8 hours Post-dose-2.8 ± 1.215.2 ± 1.185.0 ± 1.19-6.3 ± 1.18
12 hours Post-dose3.5 ± 1.4011.2 ± 1.368.8 ± 1.381.0 ± 1.36
24 hours Post-dose-1.5 ± 1.257.1 ± 1.211.7 ± 1.23-3.9 ± 1.21
36 hours Post-dose-2.1 ± 1.410.2 ± 1.360.5 ± 1.38-1.3 ± 1.36
SecondaryChange From Baseline in PR Interval

The cardio-dynamic assessment was performed through 12-lead ECGs extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The PR interval is the time from the onset of the P-wave to the start of the next QRS complex, corresponding to the end of atrial depolarization and onset of ventricular depolarization.

Time frame:
At 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, and 36 hours post-dose
Reported as:
Least squares mean · msec
Change From Baseline in PR Interval
msecTherapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mgMoxifloxacinPlacebo
0.5 hours Post-dose0.0 ± 0.83-0.7 ± 0.810.1 ± 0.820.2 ± 0.81
1 hours Post-dose0.4 ± 1.040.7 ± 1.01-0.3 ± 1.022.3 ± 1.01
1.5 hours Post-dose-1.4 ± 1.03-0.3 ± 1.00-0.4 ± 1.011.1 ± 1.00
2 hours Post-dose0.4 ± 1.04-1.3 ± 1.01-0.1 ± 1.021.6 ± 1.01
2.5 hours Post-dose-2.4 ± 1.03-2.3 ± 1.000.8 ± 1.00-1.9 ± 1.01
3 hours Post-dose-1.3 ± 1.03-1.6 ± 1.00-1.3 ± 1.010.2 ± 1.00
3.5 hours Post-dose-2.6 ± 0.97-2.8 ± 0.94-2.0 ± 0.950.1 ± 0.94
4 hours Post-dose-2.2 ± 1.04-3.4 ± 1.01-2.6 ± 1.030.1 ± 1.01
5 hours Post-dose-5.3 ± 1.20-7.3 ± 1.16-6.0 ± 1.18-3.2 ± 1.16
6 hours Post-dose-7.4 ± 1.30-9.3 ± 1.26-8.2 ± 1.28-5.5 ± 1.26
7 hours Post-dose-7.2 ± 1.30-9.8 ± 1.26-8.0 ± 1.28-5.5 ± 1.26
8 hours Post-dose-7.4 ± 1.16-9.0 ± 1.13-7.5 ± 1.15-5.2 ± 1.13
12 hours Post-dose-5.8 ± 1.39-7.9 ± 1.35-6.7 ± 1.37-3.1 ± 1.35
24 hours Post-dose-3.7 ± 1.32-3.8 ± 1.282.1 ± 1.30-0.9 ± 1.28
36 hours Post-dose-7.8 ± 1.39-9.3 ± 1.34-3.3 ± 1.36-2.6 ± 1.34
SecondaryChange From Baseline in QRS Interval

The cardio-dynamic assessment was performed through 12-lead ECGs extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. QRS interval is the time from electrocardiogram Q wave to the end of the S wave, corresponding to ventricle depolarization.

Time frame:
At 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, and 36 hours post-dose
Reported as:
Least squares mean · msec
Change From Baseline in QRS Interval
msecTherapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mgMoxifloxacinPlacebo
0.5 hours Post-dose-0.1 ± 0.140.1 ± 0.130.2 ± 0.140.2 ± 0.13
1 hours Post-dose0.2 ± 0.160.1 ± 0.160.4 ± 0.160.0 ± 0.16
1.5 hours Post-dose0.0 ± 0.160.0 ± 0.16-0.1 ± 0.16-0.1 ± 0.16
2 hours Post-dose-0.1 ± 0.150.2 ± 0.150.2 ± 0.150.0 ± 0.15
2.5 hours Post-dose-0.1 ± 0.170.2 ± 0.160.3 ± 0.160.1 ± 0.16
3 hours Post-dose0.1 ± 0.170.4 ± 0.170.3 ± 0.170.3 ± 0.17
3.5 hours Post-dose0.1 ± 0.180.5 ± 0.170.1 ± 0.180.3 ± 0.17
4 hours Post-dose0.1 ± 0.200.4 ± 0.190.3 ± 0.200.2 ± 0.19
5 hours Post-dose0.1 ± 0.270.5 ± 0.260.3 ± 0.270.5 ± 0.26
6 hours Post-dose-0.4 ± 0.24-0.3 ± 0.24-0.4 ± 0.24-0.2 ± 0.24
7 hours Post-dose-0.7 ± 0.24-0.6 ± 0.23-0.5 ± 0.23-0.2 ± 0.23
8 hours Post-dose-0.5 ± 0.220.1 ± 0.21-0.2 ± 0.21-0.2 ± 0.21
12 hours Post-dose0.2 ± 0.30-0.2 ± 0.290.1 ± 0.290.3 ± 0.29
24 hours Post-dose-0.3 ± 0.390.1 ± 0.38-0.5 ± 0.39-0.3 ± 0.38
36 hours Post-dose-0.4 ± 0.27-0.4 ± 0.26-0.5 ± 0.26-0.3 ± 0.26
SecondaryChange From Baseline in Heart Rate (HR) Interval

The cardio-dynamic assessment was performed through 12-lead ECGs extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. Baseline is defined as the last results (scheduled or unscheduled) obtained prior to drug administration in each period.

Time frame:
At 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, and 36 hours post-dose
Reported as:
Least squares mean · beats per minute (bpm)
Change From Baseline in Heart Rate (HR) Interval
beats per minute (bpm)Therapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mgMoxifloxacinPlacebo
0.5 hours Post-dose0.6 ± 0.761.1 ± 0.751.3 ± 0.750.5 ± 0.75
1 hours Post-dose1.2 ± 0.852.8 ± 0.832.3 ± 0.841.1 ± 0.83
1.5 hours Post-dose3.3 ± 0.855.1 ± 0.831.9 ± 0.841.1 ± 0.84
2 hours Post-dose3.7 ± 0.867.8 ± 0.841.4 ± 0.851.1 ± 0.84
2.5 hours Post-dose3.8 ± 0.999.9 ± 0.970.9 ± 0.980.5 ± 0.97
3 hours Post-dose4.3 ± 0.8610.5 ± 0.841.4 ± 0.850.7 ± 0.84
3.5 hours Post-dose4.0 ± 0.899.9 ± 0.872.2 ± 0.880.1 ± 0.87
4 hours Post-dose4.3 ± 0.9411.0 ± 0.922.3 ± 0.931.3 ± 0.92
5 hours Post-dose15.0 ± 1.0022.1 ± 0.9810.6 ± 0.9910.5 ± 0.98
6 hours Post-dose12.4 ± 1.1021.7 ± 1.0710.2 ± 1.0810.4 ± 1.07
7 hours Post-dose8.2 ± 1.0417.0 ± 1.027.5 ± 1.036.7 ± 1.02
8 hours Post-dose7.4 ± 0.8814.0 ± 0.866.2 ± 0.875.6 ± 0.86
12 hours Post-dose9.5 ± 1.1412.7 ± 1.1110.6 ± 1.1310.6 ± 1.11
24 hours Post-dose0.6 ± 0.802.1 ± 0.791.6 ± 0.802.2 ± 0.79
36 hours Post-dose9.1 ± 1.188.1 ± 1.1510.2 ± 1.169.9 ± 1.15
SecondaryPlacebo-corrected Change From Baseline in PR Interval

Placebo-corrected change from Baseline in PR, (ΔΔPR) was calculated based on model-predicted effect. PR interval was the time between the beginning of the P wave and the start of the QRS interval, corresponding to the end of atrial depolarization and onset of ventricular depolarization.

Time frame:
At 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, and 36 hours post-dose
Reported as:
Least squares mean · msec
Placebo-corrected Change From Baseline in PR Interval
msecTherapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mgMoxifloxacin
0.5 hours Post-dose-0.2 ± 1.02-0.9 ± 1.00-0.1 ± 1.01
1 hour Post-dose-1.9 ± 1.34-1.6 ± 1.31-2.6 ± 1.32
1.5 hours Post-dose-2.6 ± 1.33-1.5 ± 1.30-1.6 ± 1.31
2 hours Post-dose-1.2 ± 1.34-2.9 ± 1.31-1.7 ± 1.32
2.5 hours Post-dose-3.2 ± 1.32-3.1 ± 1.30-2.6 ± 1.31
3 hour Post-dose-1.4 ± 1.32-1.8 ± 1.30-1.5 ± 1.31
3.5 hours Post-dose-2.7 ± 1.23-2.9 ± 1.21-2.1 ± 1.22
4 hours Post-dose-2.3 ± 1.35-3.5 ± 1.32-2.6 ± 1.33
5 hours Post-dose-2.1 ± 1.57-4.1 ± 1.55-2.8 ± 1.56
6 hours Post-dose-1.9 ± 1.73-3.8 ± 1.70-2.7 ± 1.71
7 hours Post-dose-1.7 ± 1.73-4.3 ± 1.70-2.5 ± 1.71
8 hours Post-dose-2.2 ± 1.53-3.8 ± 1.50-2.3 ± 1.51
12 hours Post-dose-2.7 ± 1.85-4.7 ± 1.82-3.6 ± 1.84
24 hours Post-dose-2.8 ± 1.76-2.9 ± 1.733.0 ± 1.74
36 hours Post-dose-5.2 ± 1.85-6.6 ± 1.82-0.7 ± 1.83
SecondaryPlacebo-corrected Change From Baseline in QRS Interval

Placebo-corrected change from baseline for QRS interval, (ΔΔQRS) was calculated based on model-predicted effect. QRS interval is the time from Q wave to the end of the S wave, corresponding to ventricle depolarization.

Time frame:
At 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, and 36 hours post-dose
Reported as:
Least squares mean · msec
Placebo-corrected Change From Baseline in QRS Interval
msecTherapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mgMoxifloxacin
0.5 hours Post-dose-0.2 ± 0.170.0 ± 0.160.1 ± 0.17
1 hours Post-dose0.1 ± 0.210.1 ± 0.200.4 ± 0.20
1.5 hours Post-dose0.1 ± 0.210.1 ± 0.200.0 ± 0.20
2 hours Post-dose0.0 ± 0.190.2 ± 0.190.3 ± 0.19
2.5 hours Post-dose-0.2 ± 0.210.1 ± 0.200.2 ± 0.21
3 hours Post-dose-0.2 ± 0.220.1 ± 0.220.0 ± 0.22
3.5 hours Post-dose-0.3 ± 0.230.2 ± 0.23-0.2 ± 0.23
4 hours Post-dose0.0 ± 0.260.2 ± 0.260.2 ± 0.26
5 hours Post-dose-0.3 ± 0.370.0 ± 0.36-0.2 ± 0.36
6 hours Post-dose-0.2 ± 0.320.0 ± 0.32-0.1 ± 0.32
7 hours Post-dose-0.5 ± 0.32-0.4 ± 0.31-0.3 ± 0.31
8 hours Post-dose-0.3 ± 0.280.2 ± 0.280.0 ± 0.28
12 hours Post-dose0.0 ± 0.40-0.5 ± 0.39-0.1 ± 0.40
24 hours Post-dose0.1 ± 0.540.4 ± 0.53-0.1 ± 0.53
36 hours Post-dose-0.1 ± 0.36-0.1 ± 0.35-0.2 ± 0.36
SecondaryPlacebo-corrected Change From Baseline in HR Interval

Placebo-corrected change from baseline in HR, (ΔΔHR) was calculated based on model-predicted effect.

Time frame:
At 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, and 36 hours post-dose
Reported as:
Least squares mean · bpm
Placebo-corrected Change From Baseline in HR Interval
bpmTherapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mgMoxifloxacin
0.5 hours Post-dose0.1 ± 0.730.6 ± 0.710.8 ± 0.72
1 hours Post-dose0.1 ± 0.891.6 ± 0.881.2 ± 0.88
1.5 hours Post-dose2.2 ± 0.904.0 ± 0.880.8 ± 0.89
2 hours Post-dose2.6 ± 0.926.7 ± 0.900.3 ± 0.91
2.5 hours Post-dose3.3 ± 1.159.3 ± 1.130.3 ± 1.14
3 hours Post-dose3.6 ± 0.919.8 ± 0.900.7 ± 0.91
3.5 hours Post-dose3.9 ± 0.969.8 ± 0.952.1 ± 0.96
4 hours Post-dose3.0 ± 1.069.7 ± 1.041.0 ± 1.05
5 hours Post-dose4.5 ± 1.1711.6 ± 1.150.1 ± 1.16
6 hours Post-dose1.9 ± 1.3211.2 ± 1.29-0.3 ± 1.31
7 hours Post-dose1.4 ± 1.2310.2 ± 1.210.7 ± 1.22
8 hours Post-dose1.9 ± 0.958.5 ± 0.930.7 ± 0.94
12 hours Post-dose-1.1 ± 1.392.1 ± 1.37-0.1 ± 1.38
24 hours Post-dose-1.6 ± 0.82-0.2 ± 0.80-0.7 ± 0.81
36 hours Post-dose-0.8 ± 1.45-1.8 ± 1.430.3 ± 1.44
SecondaryNumber of Participants With Changes in Categorical Outliers for QTcF, PR, and QRS Intervals in the ECG and HR

QTcF: Treatment-emergent value of greater than (\>) 450 and less than or equal to (\<=) 480 ms when not present at Baseline (new onset). Treatment-emergent value of \> 480 and \<= 500 ms when not present at Baseline (new onset). Treatment-emergent value of \> 500 ms when not present at Baseline (new onset). Increase of QTcF (ΔQTcF) from Baseline of \> 30 and \<= 60 ms. Increase of QTcF from Baseline \> 60 ms HR: Decrease of HR from Baseline \> 25% resulting in HR less than (\<) 50 bpm. Increase of HR from Baseline \> 25% resulting in HR \> 100 bpm. PR: Increase of PR from Baseline \> 25% resulting in PR \> 210 ms. QRS: Increase of QRS from Baseline \> 25% resulting in QRS \> 120 ms.

Time frame:
Baseline, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, and 36 hours post-dose
Reported as:
Count of participants · Participants
Number of Participants With Changes in Categorical Outliers for QTcF, PR, and QRS Intervals in the ECG and HR
ParticipantsTherapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mgMoxifloxacinPlacebo
QTcF > 450 and <= 480 ms0120
QTcF > 480 and <= 500 ms0000
QTcF > 500 ms0000
ΔQTcF > 30 and <= 60 ms0220
ΔQTcF > 60 ms0000
HR < 50 (bpm) with a decrease in ΔHR > 25%0000
HR > 100 (bpm) with an increase in ΔHR > 25%0000
PR > 210 (ms) with an increase in ΔPR > 25%0000
QRS > 120 (ms) with an increase in ΔQRS > 25%0000
SecondaryNumber of Participants With Treatment-Emergent Changes of T-Wave Morphology and U Wave Presence

T-wave abnormalities were categorized as follows: Normal T wave (+): Any positive T wave not meeting any criterion below. Flat T wave: T amplitude \< 1 mm (either positive or negative) including flat isoelectric line. Notched T wave (+): Presence of notch(es) of at least 0.05 mV amplitude on ascending or descending arm of the positive T wave. Biphasic: T wave that contains a second component with an opposite phase that is at least 0.1 mV deep (both positive/negative and negative/positive and polyphasic T waves included). Normal T wave (-): T amplitude that is negative, without biphasic T wave or notches. Notched T wave (-): Presence of notch(es) of at least 0.05 mV amplitude on descending or ascending arm of the negative T wave. U waves: Presence of abnormal U waves.

Time frame:
Up to 44 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Changes of T-Wave Morphology and U Wave Presence
ParticipantsTherapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mgMoxifloxacinPlacebo
Flat0000
Notched (+)0000
Biphasic0000
Normal (-)0000
Notched (-)0000
U-Wave presence0000
SecondaryPlasma Pharmacokinetic (PK): Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of ITF2357 and Its Metabolites

The area under the concentration time curve (AUC) from time zero (= dosing time) to the last sampling time (tlast) at which the concentration is at or above the lower limit of quantification. AUC0-t was calculated using the mixed log-linear trapezoidal rule (linear up, log down). AUC0-t of ITF2357 and metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide were reported.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Reported as:
Geometric mean · hours*nanograms per milliliter (h*ng/mL)
Plasma Pharmacokinetic (PK): Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of ITF2357 and Its Metabolites
hours*nanograms per milliliter (h*ng/mL)Therapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mg
ITF2357596.10 ± 22.572313.44 ± 20.53
ITF2374363.55 ± 63.831296.22 ± 59.65
ITF23752672.92 ± 54.889599.11 ± 52.70
ITF24405696.28 ± 23.3618577.74 ± 21.34
ITF25631247.92 ± 23.583563.33 ± 20.59
ITF2955 glucuronide1.53 ± 78.0015.89 ± 47.69
SecondaryPlasma PK: Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Moxifloxacin

The area under the concentration time curve (AUC) from time zero (= dosing time) to the last sampling time (tlast) at which the concentration is at or above the lower limit of quantification. AUC0-t was calculated using the mixed log-linear trapezoidal rule (linear up, log down).

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Reported as:
Geometric mean · h*ng/mL
Plasma PK: Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Moxifloxacin
h*ng/mLMoxifloxacin
Plasma PK: Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Moxifloxacin27077.52 ± 16.17
SecondaryPlasma PK: Area Under the Concentration-Time Curve From Time Zero to 12 Hours (AUC0-12) of ITF2357 and Its Metabolites

AUC0-12 was calculated using the trapezoidal method for ITF2357 and metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide. AUC0-12:: of ITF2357 and its metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide were reported.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 12 hours post-dose
Reported as:
Mean · h*ng/mL
Plasma PK: Area Under the Concentration-Time Curve From Time Zero to 12 Hours (AUC0-12) of ITF2357 and Its Metabolites
h*ng/mLTherapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mg
ITF2357480.70 ± 114.091893.60 ± 423.33
ITF2374178.10 ± 81.57607.16 ± 258.73
ITF23751680.76 ± 725.806018.02 ± 2430.06
ITF24401448.97 ± 362.633924.21 ± 1130.05
ITF2563299.77 ± 85.39776.22 ± 259.98
ITF2955 glucuronide0.88 ± 1.6218.08 ± 8.39
SecondaryPlasma PK: Area Under the Concentration-Time Curve From Time Zero to 12 Hours (AUC0-12) of Moxifloxacin

AUC0-12 was calculated using the trapezoidal method for Moxifloxacin.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8 and 12 hours post-dose
Reported as:
Mean · h*ng/mL
Plasma PK: Area Under the Concentration-Time Curve From Time Zero to 12 Hours (AUC0-12) of Moxifloxacin
h*ng/mLMoxifloxacin
Plasma PK: Area Under the Concentration-Time Curve From Time Zero to 12 Hours (AUC0-12) of Moxifloxacin13625.09 ± 2733.45
SecondaryPlasma PK: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of ITF2357 and Its Metabolites

AUC0-inf was calculated as AUC0-t + Clast/Kel, where Clast is the last measurable concentration. Elimination rate constant (Kel),was defined as the negative of the estimated slope of the linear regression of the in-transformed concentration versus time profile in the terminal elimination phase. AUC0-inf of ITF2357 and metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide were reported.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Reported as:
Mean · h*ng/mL
Plasma PK: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of ITF2357 and Its Metabolites
h*ng/mLTherapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mg
ITF2357626.57 ± 139.542383.27 ± 484.72
ITF2374475.82 ± 318.251555.70 ± 986.40
ITF23753246.97 ± 1806.5211373.93 ± 6045.30
ITF24406196.74 ± 1400.6019920.16 ± 4134.67
ITF25631357.46 ± 290.513864.88 ± 757.94
ITF2955 glucuronide10.2020.68 ± 9.56
SecondaryPlasma PK: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Moxifloxacin

AUC0-inf was calculated as AUC0-t + Clast/Kel, where Clast is the last measurable concentration for Moxifloxacin.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Reported as:
Mean · h*ng/mL
Plasma PK: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Moxifloxacin
h*ng/mLMoxifloxacin
Plasma PK: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Moxifloxacin28327.15 ± 4616.50
SecondaryPlasma PK: Percentage of Residual Area for ITF2357 and Its Metabolites

Residual area was calculated as 100\*(1- AUC0-t / AUC0-inf) for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Reported as:
Mean · Percentage of residual area
Plasma PK: Percentage of Residual Area for ITF2357 and Its Metabolites
Percentage of residual areaTherapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mg
ITF23572.63 ± 0.840.95 ± 0.36
ITF23748.49 ± 4.233.72 ± 2.82
ITF23753.45 ± 2.281.70 ± 1.25
ITF24405.81 ± 3.094.69 ± 3.58
ITF25636.04 ± 4.535.95 ± 4.42
ITF2955 glucuronide66.0724.01 ± 6.03
SecondaryPlasma PK: Percentage of Residual Area for Moxifloxacin

Residual area was calculated as 100\*(1- AUC0-t / AUC0-inf) for moxifloxacin.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Reported as:
Geometric mean · Percentage of residual area
Plasma PK: Percentage of Residual Area for Moxifloxacin
Percentage of residual areaMoxifloxacin
Plasma PK: Percentage of Residual Area for Moxifloxacin2.81 ± 48.66
SecondaryPlasma PK: Maximum Observed Plasma Concentration (Cmax) of ITF2357 and Its Metabolites

Cmax was calculated for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide. Cmax was taken directly from the observed concentration-time curve.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Reported as:
Mean · ng/mL
Plasma PK: Maximum Observed Plasma Concentration (Cmax) of ITF2357 and Its Metabolites
ng/mLTherapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mg
ITF2357102.84 ± 30.55409.65 ± 133.74
ITF237424.39 ± 11.0181.59 ± 32.93
ITF2375258.64 ± 111.23820.75 ± 273.52
ITF2440195.23 ± 45.41602.02 ± 142.15
ITF256343.90 ± 13.03123.27 ± 31.02
ITF2955 glucuronide0.42 ± 0.624.41 ± 1.70
SecondaryPlasma PK: Maximum Observed Plasma Concentration (Cmax) of Moxifloxacin

Cmax was calculated for moxifloxacin. Cmax was taken directly from the observed concentration-time curve.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Reported as:
Mean · ng/mL
Plasma PK: Maximum Observed Plasma Concentration (Cmax) of Moxifloxacin
ng/mLMoxifloxacin
Plasma PK: Maximum Observed Plasma Concentration (Cmax) of Moxifloxacin1789.49 ± 498.08
SecondaryPlasma PK: Time of Observed Cmax (Tmax) of ITF2357 and Its Metabolites

Tmax was calculated for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide. The time to reach the maximum observed plasma concentration obtained directly from plasma concentration time curve.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Reported as:
Median · hours
Plasma PK: Time of Observed Cmax (Tmax) of ITF2357 and Its Metabolites
hoursTherapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mg
ITF23572.139 (1.099 to 3.355)2.158 (1.165 to 5.092)
ITF23745.098 (5.089 to 6.298)5.634 (5.093 to 7.094)
ITF23753.610 (2.153 to 4.101)4.094 (2.599 to 5.101)
ITF244012.144 (8.090 to 12.238)12.152 (12.134 to 12.228)
ITF256312.146 (7.100 to 12.238)12.152 (8.090 to 12.228)
ITF2955 glucuronide0 (0 to 3.604)2.606 (1.596 to 4.093)
SecondaryPlasma PK: Time of Observed Cmax (Tmax) of Moxifloxacin

Tmax was calculated for Moxifloxacin. The time to reach the maximum observed plasma concentration obtained directly from plasma concentration time curve.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Reported as:
Mean · hours
Plasma PK: Time of Observed Cmax (Tmax) of Moxifloxacin
hoursMoxifloxacin
Plasma PK: Time of Observed Cmax (Tmax) of Moxifloxacin2.327 (0.615 to 4.095)
SecondaryPlasma PK: Elimination Rate Constant (Kel) of ITF2357 and Its Metabolites

Kel was defined as the negative of the estimated slope of the linear regression of the ln-transformed concentration versus time profile in the terminal elimination phase. Kel was calculated for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, andITF2955 glucuronide.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Reported as:
Mean · fraction per hour
Plasma PK: Elimination Rate Constant (Kel) of ITF2357 and Its Metabolites
fraction per hourTherapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mg
ITF23570.0923 ± 0.01980.0652 ± 0.0146
ITF23740.0570 ± 0.01410.0549 ± 0.0175
ITF23750.0585 ± 0.01570.0667 ± 0.0130
ITF24400.0508 ± 0.01260.0530 ± 0.0124
ITF25630.0499 ± 0.01380.0498 ± 0.0156
ITF2955 glucuronide0.15140.2886 ± 0.0944
SecondaryPlasma PK: Elimination Rate Constant (Kel) of Moxifloxacin

Kel was defined as the negative of the estimated slope of the linear regression of the ln-transformed concentration versus time profile in the terminal elimination phase. Kel was calculated for Moxifloxacin.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Reported as:
Mean · fraction per hour
Plasma PK: Elimination Rate Constant (Kel) of Moxifloxacin
fraction per hourMoxifloxacin
Plasma PK: Elimination Rate Constant (Kel) of Moxifloxacin0.0493 ± 0.0091
SecondaryPlasma PK: Elimination Half-life (T½ el) of ITF2357 and Its Metabolites

T½ el was calculated as ln(2)/kel for ITF2357 and Metabolites : ITF2374, ITF2375, ITF2440, ITF2563, ITF2955 glucuronide, and Moxifloxacin.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Reported as:
Median · hours
Plasma PK: Elimination Half-life (T½ el) of ITF2357 and Its Metabolites
hoursTherapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mg
ITF23577.25 (5.47 to 13.69)11.19 (6.26 to 16.35)
ITF237412.63 (9.08 to 26.30)12.49 (8.27 to 22.07)
ITF237512.31 (8.38 to 16.77)10.71 (7.97 to 13.86)
ITF244012.91 (9.94 to 22.65)13.07 (9.48 to 20.87)
ITF256313.47 (9.76 to 29.08)13.33 (9.56 to 23.00)
ITF2955 glucuronide4.58 (4.58 to 4.58)2.27 (1.62 to 4.49)
SecondaryPlasma PK: Elimination Half-life (T½ el) of Moxifloxacin

T½ el was calculated as ln(2)/kel for moxifloxacin.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Reported as:
Median · hours
Plasma PK: Elimination Half-life (T½ el) of Moxifloxacin
hoursMoxifloxacin
Plasma PK: Elimination Half-life (T½ el) of Moxifloxacin13.97 (9.96 to 20.83)
SecondaryPlasma PK: Apparent Total Body Clearance (CL/F) of ITF2357 and Its Metabolites

CL/F was calculated as Dose/AUC0-inf for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Reported as:
Mean · liters per hour
Plasma PK: Apparent Total Body Clearance (CL/F) of ITF2357 and Its Metabolites
liters per hourTherapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mg
ITF2357167.12 ± 36.40131.11 ± 27.51
ITF2374296.86 ± 172.71251.84 ± 124.72
ITF237543.11 ± 27.8036.69 ± 23.96
ITF244016.94 ± 4.0115.73 ± 3.60
ITF256376.77 ± 16.3380.71 ± 17.61
ITF2955 glucuronide9808.0316631.81 ± 5576.18
SecondaryPlasma PK: Apparent Total Body Clearance (CL/F) of Moxifloxacin

CL/F was calculated as Dose/AUC0-inf for moxifloxacin.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Reported as:
Mean · liters per hour
Plasma PK: Apparent Total Body Clearance (CL/F) of Moxifloxacin
liters per hourMoxifloxacin
Plasma PK: Apparent Total Body Clearance (CL/F) of Moxifloxacin14.49 ± 2.39
SecondaryPlasma PK: Apparent Volume of Distribution (Vd/F) of ITF2357 and Its Metabolites

Vd/F was calculated as Dose/Kel x AUC0-inf for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, and ITF2955 glucuronide.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Reported as:
Mean · liters
Plasma PK: Apparent Volume of Distribution (Vd/F) of ITF2357 and Its Metabolites
litersTherapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mg
ITF23571897.03 ± 588.152125.49 ± 764.32
ITF23745094.92 ± 2676.375027.46 ± 3106.93
ITF2375795.34 ± 636.25576.42 ± 436.72
ITF2440354.01 ± 123.39311.58 ± 96.04
ITF25631702.58 ± 749.671757.38 ± 556.98
ITF2955 glucuronide64779.3758366.39 ± 12977.61
SecondaryPlasma PK: Apparent Volume of Distribution (Vd/F) of Moxifloxacin

Vd/F was calculated as Dose/Kel x AUC0-inf for moxifloxacin.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, and 72 hours post-dose
Reported as:
Mean · liters
Plasma PK: Apparent Volume of Distribution (Vd/F) of Moxifloxacin
litersMoxifloxacin
Plasma PK: Apparent Volume of Distribution (Vd/F) of Moxifloxacin303.02 ± 72.21
SecondaryUrine PK: Cumulative Urinary Excretion From Time Zero to Time t (Ae0-t) for ITF2357 and Its Metabolites

Ae0-t was calculated as the sum of the amounts excreted over each collection interval. The amount excreted in the urine for each time interval is calculated as the urine concentration multiplied by the urine volume for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, ITF2955 glucuronide.

Time frame:
Pre-dose (within 2 hours before dosing), 0-8 hours, 8-24 hours, 24-48 hours, and 48-72 hours post-dose
Reported as:
Mean · Nanograms (ng)
Urine PK: Cumulative Urinary Excretion From Time Zero to Time t (Ae0-t) for ITF2357 and Its Metabolites
Nanograms (ng)Therapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mg
ITF23571304747.81 ± 444627.394284095.88 ± 1031461.74
ITF23741526630.97 ± 820295.424634585.90 ± 2469826.92
ITF2375330005.73 ± 244198.091051751.97 ± 702770.77
ITF244020496643.63 ± 3002369.9655319154.12 ± 9058968.83
ITF25639746260.02 ± 1204246.0327259547.79 ± 4213356.29
ITF2955 glucuronide13456.18 ± 3086.5366582.99 ± 18731.80
SecondaryUrine PK: Maximum Rate of Urinary Excretion (Rmax) for ITF2357 and Its Metabolites

Rmax was calculated by dividing the amount of drug excreted in each collection interval by the time over which it was collected for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, ITF2955 glucuronide.

Time frame:
Pre-dose (within 2 hours before dosing), 0-8 hours, 8-24 hours, 24-48 hours, and 48-72 hours post-dose
Reported as:
Mean · Nanogram per hour (ng/h)
Urine PK: Maximum Rate of Urinary Excretion (Rmax) for ITF2357 and Its Metabolites
Nanogram per hour (ng/h)Therapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mg
ITF2357304920.74 ± 327302.131224735.12 ± 922878.78
ITF2374155698.10 ± 166313.02536094.03 ± 361645.28
ITF237551562.37 ± 46045.34182276.01 ± 172602.20
ITF24401323571.78 ± 414580.113469056.76 ± 1554749.72
ITF2563712846.46 ± 298304.191986177.40 ± 904296.76
ITF2955 glucuronide5170.46 ± 4743.7825858.22 ± 23838.45
SecondaryUrine PK: Time of Rmax (TRmax) for ITF2357 and Its Metabolites

TRmax was calculated as the midpoint of the collection interval during which Rmax occurred for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, ITF2955 glucuronide.

Time frame:
Pre-dose (within 2 hours before dosing), 0-8 hours, 8-24 hours, 24-48 hours, and 48-72 hours post-dose
Reported as:
Median · hours
Urine PK: Time of Rmax (TRmax) for ITF2357 and Its Metabolites
hoursTherapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mg
ITF23571.84 (0.34 to 3.77)1.49 (0.36 to 9.39)
ITF23744.40 (0.34 to 11.01)1.49 (0.36 to 10.01)
ITF23751.84 (0.34 to 10.01)1.49 (0.36 to 9.39)
ITF24407.24 (0.34 to 11.01)6.65 (0.36 to 22.17)
ITF25637.24 (0.34 to 11.01)6.65 (0.36 to 10.01)
ITF2955 glucuronide1.84 (0.34 to 3.77)1.49 (0.36 to 3.79)
SecondaryUrine PK: Renal Clearance (Clr) for ITF2357 and Its Metabolites

Clr was calculated as Ae0-t / AUC0-t (plasma) for ITF2357 and Metabolites: ITF2374, ITF2375, ITF2440, ITF2563, ITF2955 glucuronide.

Time frame:
Pre-dose (within 2 hours before dosing), 0-8 hours, 8-24 hours, 24-48 hours, and 48-72 hours post-dose
Reported as:
Mean · L/h
Urine PK: Renal Clearance (Clr) for ITF2357 and Its Metabolites
L/hTherapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mg
ITF23572127.55 ± 402.631859.30 ± 360.82
ITF23743856.29 ± 979.363403.49 ± 1004.83
ITF2375103.35 ± 27.9496.02 ± 29.26
ITF24403629.92 ± 717.292994.15 ± 583.57
ITF25637879.16 ± 1464.337666.41 ± 1279.54
ITF2955 glucuronide16623.97 ± 22459.534215.01 ± 1176.29
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

Adverse event (AE) was defined as any untoward medical occurrence in a subject or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with the study drug. Serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; required initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE were defined as an AEs following the start of treatment or AEs increasing in severity during treatment. TEAEs include both serious and non-serious TEAEs.

Time frame:
Baseline up to 44 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsTherapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mgPlaceboMoxifloxacin
Participants with TEAEs51546
Participants with Serious TEAEs0000
SecondaryNumber of Treatment-Related TEAEs

Adverse event (AE) was defined as any untoward medical occurrence in a subject or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with the study drug. Any AEs which occurred due to study drug treatment are reported as Treatment-related AEs. Number of treatment related TEAEs were reported.

Time frame:
Baseline up to 44 days
Reported as:
Number · number of events
Number of Treatment-Related TEAEs
number of eventsTherapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mgPlaceboMoxifloxacin
Number of Treatment-Related TEAEs62064
SecondaryNumber of TEAEs Based on Severity

All AEs were analyzed using National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0 and were graded as Grade 1: mild asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated, Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL), Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL, Grade 4: Life-threatening consequences; urgent intervention indicated, Grade 5: death related AE, where higher grade indicated more severe condition. Number of TEAEs based on severity were reported.

Time frame:
Baseline up to 44 days
Reported as:
Number · number of events
Number of TEAEs Based on Severity
number of eventsTherapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mgPlaceboMoxifloxacin
Mild62186
Moderate0400
Severe0000
SecondaryNumber of Participants With Clinically Significant Changes in Vital Signs

Vital signs, including semi supine blood pressure, pulse rate, respiratory rate, weight, and oral temperature were assessed. Clinical significance was decided by the investigator. Number of participants with clinically significant change from baseline in vital signs were reported.

Time frame:
Baseline up to 44 days
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Vital Signs
ParticipantsTherapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mgPlaceboMoxifloxacin
Number of Participants With Clinically Significant Changes in Vital Signs0000
SecondaryNumber of Participants With Clinically Significant Changes in Clinical Laboratory Parameters

Clinical laboratory parameters included biochemistry, hematology, and urinalysis. Clinical significance was decided by the investigator. Number of participants with clinically significant change from baseline in clinical laboratory parameters were reported.

Time frame:
Baseline up to 44 days
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters
ParticipantsTherapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mgPlaceboMoxifloxacin
Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters0200
SecondaryNumber of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Findings

ECG parameters included rhythm, ventricular rate, PR interval, QRS duration, and QT interval. Clinical significance was decided by the investigator. Number of participants with clinically significant change from baseline in ECG were reported.

Time frame:
Baseline up to 44 days
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Findings
ParticipantsTherapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mgPlaceboMoxifloxacin
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Findings0000

Adverse events

Collected over Baseline up to 44 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Therapeutic Dose: ITF2357 100 mg0/29 (0%)0/29 (0%)5/29 (17.2%)
Supratherapeutic Dose: ITF2357 300 mg0/31 (0%)0/31 (0%)15/31 (48.4%)
Placebo0/31 (0%)0/31 (0%)6/31 (19.4%)
Moxifloxacin0/31 (0%)0/31 (0%)4/31 (12.9%)
Most frequent other events
Showing 10 of 23
Most frequent other events
EventTherapeutic Dose: ITF2357 100 mgSupratherapeutic Dose: ITF2357 300 mgPlaceboMoxifloxacin
NauseaGastrointestinal disorders0/295/310/312/31
HeadacheNervous system disorders1/294/311/310/31
Abdominal discomfortGastrointestinal disorders0/293/310/310/31
DiarrhoeaGastrointestinal disorders2/291/312/310/31
DizzinessNervous system disorders1/290/310/310/31
Sensation of foreign bodyGeneral disorders1/290/310/310/31
Back painMusculoskeletal and connective tissue disorders1/291/310/310/31
Pain in jawMusculoskeletal and connective tissue disorders1/290/310/310/31
Abdominal painGastrointestinal disorders0/291/311/310/31
ConstipationGastrointestinal disorders0/291/310/311/31

Baseline characteristics

Safety population included all participants who had received at least 1 dose of study drug (therapeutic and supratherapeutic doses of ITF2357, moxifloxacin, or placebo). All participants had multiple movement within the arms of the study at different levels and unique participants baseline was not analyzed, only overall participant data was planned, analyzed and reported to avoid double-counting.

Age, Continuous
Age, Continuous(years)All Participants
Mean40.6 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female12
Male19
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino10
Not Hispanic or Latino21
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American3
White27
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Québec
    Québec, G1P 0A2, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Jun 2021, 2 months.

Results were first posted in Jan 2024, 2 years 6 months after primary completion.

Of 28 phase 1 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2021
First posted
Mar 29, 2021
StartActual
Apr 13, 2021
Primary completionActual
Jun 18, 2021
CompletionActual
Jun 18, 2021
Results first posted
Jan 11, 2024
Last update
Jan 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04821063
Lead sponsor
Italfarmaco
Responsible party
Sponsor
First posted
Mar 29, 2021
Start date
Apr 13, 2021
Primary completion
Jun 18, 2021
Completion
Jun 18, 2021
Results posted
Jan 11, 2024
Last update
Jan 11, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Givinostat

Start the discussion